Atlas Trials

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Clinical trial NCT03529123 · COMPLETED

Trial details

NCT number
NCT03529123
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 Diabetes Mellitus
Start date
2018-06-19
Primary completion
2019-11-25
Enrollment
247

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.